Abstract
Chimeric antigen receptor modified T cells targeting CD19 and CD20 have shown activity in Phase I, II trials of patients with hematological malignancies. We conducted a systematic review and meta-analysis of all published clinical trials studying the role of efficacy as well as safety of CD-19 and CD-20 chimeric antigen receptor-T therapy for B-cell hematologic malignancies. A total of 16 studies with 195 patients were identified. The pooled analysis showed an overall response rate of 61% (118/195) with complete response of 42% (81/195) and partial response of 19% (37/195). Major adverse events were cytokine release syndrome 33%, neurotoxicity 33% and B-cell aplasia 54%. Collectively, the results indicate encouraging response in relapsed/refractory B lymphoma and leukemia, especially in acute lymphoblastic leukemia (ALL) patients.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 979-993 |
| Number of pages | 15 |
| Journal | Immunotherapy |
| Volume | 9 |
| Issue number | 12 |
| DOIs | |
| State | Published - Sep 2017 |
Keywords
- chimeric antigen T cells
- hematological malignancy
- leukemia
- lymphoma
- refractory
- relapse
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology